HCPCS Level II C9081: Idecabtagene vicleucel, Autologous Anti-BCMA CAR-T

HCPCS Level II code C9081 denotes idecabtagene vicleucel, an autologous anti-BCMA CAR-T cell therapy delivered as a single therapeutic dose including leukapheresis and dose preparation. This high-cost, specialized biologic therapy is nationally significant due to its role in treating relapsed or refractory hematologic malignancies and the complex care pathway it entails, from cell collection through manufacturing to infusion.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coverage considerations across major payers, typical sites of service and clinical delivery settings, and context about why an HCPCS Level II code for a specific CAR-T product matters for billing, prior authorization, and care coordination. The publication also outlines available benchmarks and policy update trends relevant to high-cost cellular therapies and highlights areas where payers and providers commonly align or diverge in administrative practices.

The content is intended for clinicians, billing professionals, and policy analysts seeking a concise national summary of the code, its clinical purpose, and the payer landscape for idecabtagene vicleucel.

Billing Code Overview

HCPCS Level II code C9081 represents idecabtagene vicleucel, a personalized autologous cellular therapy delivered as up to 460 million autologous anti-BCMA CAR-positive viable T cells per therapeutic dose. The code description includes leukapheresis and dose preparation procedures as part of the single therapeutic dose.

Service type: Autologous CAR-T cell therapy including collection and dose preparation
Typical site of service: Hospital outpatient infusion or specialized cellular therapy center

Clinical Context

A 62-year-old patient with relapsed/refractory multiple myeloma who has exhausted standard therapies is evaluated for autologous anti-BCMA CAR T-cell therapy. The workflow begins with hematology/oncology evaluation, informed consent, and baseline organ-function testing (CBC, CMP, cardiac and pulmonary assessment). Leukapheresis is scheduled to collect the patient’s T cells; the collected material is shipped to a manufacturing facility. During manufacturing, the patient may receive bridging therapy as clinically indicated. On confirmation of a viable autologous product, the patient is admitted to an inpatient or designated outpatient infusion center for lymphodepleting chemotherapy (commonly fludarabine and cyclophosphamide) followed by administration of the cellular product C9081 (idecabtagene vicleucel, up to 460 million autologous anti-BCMA CAR-positive viable T cells). Post-infusion monitoring is intensive for cytokine release syndrome (CRS), neurotoxicity (ICANS), cytopenias, infections, and other complications; care includes daily assessments, laboratory monitoring, and supportive treatments (tocilizumab, corticosteroids, antimicrobials, transfusions) as indicated. Discharge occurs once the patient is clinically stable with an established outpatient monitoring plan and clear return precautions.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	When work, time, or intensity for the procedure is substantially greater than typical

Taxonomy Code	Specialty	Notes
`208000000X`	Hematology & Oncology	Primary specialty ordering and managing CAR T-cell therapy
`2083P0800X`	Pediatric Hematology-Oncology	When pediatric patients undergo CAR T-cell therapy (age-appropriate)
`207RC0000X`	Medical Oncology	Infusion administration oversight and systemic therapy coordination
`364S00000X`	Apheresis	Providers specializing in therapeutic apheresis and leukapheresis procedures
`2084P0800X`	Hematology	Diagnosis, pre‑treatment evaluation, and post-infusion management

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C90.00`	Multiple myeloma not having achieved remission	Common indication for BCMA-targeted CAR T-cell therapy
`C90.01`	Multiple myeloma in remission	Represents disease status; therapy may be considered in relapse/active disease contexts
`D47.2`	Monoclonal gammopathy of undetermined significance	Precursor plasma-cell disorder relevant for diagnostic context
`C90.02`	Multiple myeloma, in relapse	Indicates relapsed disease prompting consideration of CAR T therapy
`Z51.11`	Encounter for antineoplastic chemotherapy	Administrative code used for encounters involving cancer-directed systemic therapy
`T80.5XXA`	Adverse effect of transfusion, initial encounter	Relevant for documenting transfusion-related complications during peri-infusion care
`R65.21`	Severe sepsis with septic shock	Potential critical complication requiring documentation if it occurs post-infusion

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`36511`	Collection of peripheral blood stem cells; apheresis, each day	Leukapheresis performed to collect autologous T cells prior to manufacturing
`96413`	Chemotherapy administration, IV infusion, up to 1 hour; single or initial substance	Administration of lymphodepleting chemotherapy agents (e.g., fludarabine, cyclophosphamide)
`96415`	Chemotherapy administration, IV infusion, each additional hour	Used when lymphodepleting regimen requires extended infusion time
`96365`	Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour	Infusions related to supportive care, e.g., IV fluids, tocilizumab administration when given IV
`99231`	Subsequent hospital care, per day, typically 15 minutes	Daily inpatient follow-up visits for monitoring after CAR T infusion
`99417`	Prolonged clinical staff services with direct patient contact, per 15 minutes	Used when extended monitoring and management are required due to CRS or neurologic events

OpenPayer

Summary & Overview